Merck CEO Sees Legal Challenge if U.S. Adopts Drug Pricing Based on Other Countries Merck CEO Sees Legal Challenge if U.S. Adopts Drug Pricing Based on Other Countries
Merck& Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 22, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries
Merck& Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted. (Source: Reuters: Health)
Source: Reuters: Health - June 21, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Merck begins hunt for new CEO
Merck and Co. is scouting for a replacement for its CEO, Kenneth Frazier. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 20, 2019 Category: Pharmaceuticals Source Type: news

HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
Metters Was Most Recently CEO of Lycera and Previously Led Worldwide Basic Research for Merck CHARLOTTESVILLE, Va., June 19, 2019 -- (Healthcare Sales & Marketing Network) -- HemoShear Therapeutics, LLC, a privately held biotechnology company focused o... Biopharmaceuticals, Personnel HemoShear Therapeutics, REVEAL-Tx (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 19, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Keytruda (pembrolizumab) for the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
KENILWORTH, N.J.--(BUSINESS WIRE)--June 18, 2019 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 19, 2019 Category: Drugs & Pharmacology Source Type: news

Amgen, Lilly, Merck sue HHS
Amgen, Eli Lilly and Merck sued the Department of Health and Human Services in an attempt to block new rules requiring that drugmakers disclose the list price of their drugs in television ads (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 17, 2019 Category: Pharmaceuticals Source Type: news

Drug Makers Sue to Block Requirement for Listing Prices in TV Ads
The rule, set to take effect July 9, is one of the most visible efforts by the Trump administration to try to address high drug prices. (Source: NYT Health)
Source: NYT Health - June 15, 2019 Category: Consumer Health News Authors: Katie Thomas Tags: Amgen Inc Eli Lilly and Company Merck & Company Inc Health and Human Services Department Prices (Fares, Fees and Rates) Advertising and Marketing Trump, Donald J Azar, Alex M II your-feed-healthcare Source Type: news

Drugmakers sue over rule requiring prices in TV ads
Amgen, Merck and Eli Lilly say Trump administration’s move infringes on free speech (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - June 14, 2019 Category: Pharmaceuticals Source Type: news

Merck's Full Court Press On Oncology
Earlier this week, Merck entered into an agreement to acquire Tilos Therapeutics for up to $773 million. Such acquisitions demonstrate how heavily invested Merck is in immuno-oncology, an area in which it is currently well-positioned with the PD-1 inhibitor Keytruda. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 14, 2019 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Source Type: news

Merck's Full Court Press On Oncology
Earlier this week, Merck entered into an agreement to acquire Tilos Therapeutics for up to $773 million. Such acquisitions demonstrate how heavily invested Merck is in immuno-oncology, an area in which it is currently well-positioned with the PD-1 inhibitor Keytruda. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 14, 2019 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Source Type: news

IBM, Walmart, Merck in blockchain collaboration with FDA
IBM, Merck and Walmart have been chosen for a U.S. Food and Drug Administration pilot program that will explore using blockchain technology to improve the security of prescription drug supply and distribution. (Source: Reuters: Health)
Source: Reuters: Health - June 13, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

This Merck subsidiary is expanding in Albany — and hiring
IL ÚM Health Solutions plans to create 115 jobs in the Albany area over the next five years, investing $48 million. The company currently has 14 on staff at its offices at the Bull Moose Club on State Street in downtown Albany. ILÚM is a subsidiary of the pharmaceutical giant Merck& Co. Inc. (NYSE: MRK). The company is working on creating software to track drug-resistant bacteria, with the goal of slowing the spread of disease. Part of what attracted ILÚM to Albany from New Jersey is the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 12, 2019 Category: Pharmaceuticals Authors: Liz Young Source Type: news

Nebula Genomics, Merck KGaA's EMD Serono partner on lung cancer pilot
The blockchain-enabled  startup's  new pilot will rely on its database of sequenced genomes.  (Source: mobihealthnews)
Source: mobihealthnews - June 11, 2019 Category: Information Technology Source Type: news

FDA OKs Merck's Keytruda for head and neck cancer
The approval is based on a late-stage trial in which Keytruda showed a significant improvement in overall survival in cancer patients. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 11, 2019 Category: Pharmaceuticals Source Type: news

Merck's Keytruda wins FDA approval to treat head and neck cancer
Merck& Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer. (Source: Reuters: Health)
Source: Reuters: Health - June 11, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

EMD Serono Awards grant to American Cancer Society to deliver global evaluation data for SOURCE
(American Cancer Society) The American Cancer Society (ACS) has received a grant from EMD Serono Inc., the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, to improve data management for its comprehensive NGO strengthening program while building a robust community of practice among cancer-focused NGOs in low- and middle-income countries (LMIC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2019 Category: Cancer & Oncology Source Type: news

FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) June 11, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 11, 2019 Category: Drugs & Pharmacology Source Type: news

Merck to buy Tilos Therapeutics
Merck& Co. announced it was buying privately held biopharmaceutical company, Tilos Therapeutics, in a deal that could be valued at up to $773 million. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 10, 2019 Category: Pharmaceuticals Source Type: news

Merck snaps up preclinical Lexington biotech for up to $773M
Tilos Therapeutics, a quiet preclinical biotech developing treatments for cancer and autoimmune diseases, has become the latest startup to be acquired by pharmaceutical giant Merck& Co. Merck (NYSE: MRK) announced Monday that it has agreed to pay upwards of $773 million in upfront and milestone payments for the purchase. A company spokesperson declined to disclose how much Merck paid upfront. Privately held Tilos was founded in 2016 by Boehringer Ingelheim Venture Fund and Partn ers Healthcare’s… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 10, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Merck to buy Tilos Therapeutics in deal valued at up to $773 million
Merck& Co. Inc, in its second megadeal involving a cancer therapy developer in as many months, entered into a definitive agreement Monday to acquire Tilos Therapeutics in a transaction valued up to $773 million. Tilos, based in Lexington, Mass., is a biopharmaceutical company that has developed a portfolio of new drug candidates that employ a novel approach to modulating the potent signaling molecule known as TGFβ. TGFβ is believed to play an important role in the development of cancer and fibrotic… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 10, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

Three-drug combination helps curb the growth of deadly type of skin cancer
A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective new therapy for people with a specific type of advanced melanoma.The approach shows promise for extending the lives of people with a type of melanoma that contains a potent gene mutation, BRAF V600E. In clinical trials, it appeared not to cause the debilitating side effects that are caused by a combination of one targeted drug and an immunotherapy drug.The researchers found that people with the melanoma survived longer without the cancer progressing or growing when they received a combination of two targeted inhibitors that...
Source: UCLA Newsroom: Health Sciences - June 6, 2019 Category: Universities & Medical Training Source Type: news

Public health officials in New Hampshire publicly admit that MMR vaccine causes measles
(Natural News) There’s a pretty big chink forming in the armor surrounding the pro-vaccine narrative, as health officials in New Hampshire recently admitted that Merck & Co.’s combination MMR vaccine for measles, mumps, and rubella was the true cause of a measles outbreak in the area that rabid pro-vaxxers were quick to blame on the... (Source: NaturalNews.com)
Source: NaturalNews.com - June 6, 2019 Category: Consumer Health News Source Type: news

Merck Opens Application Phase for Next Accelerator
Merck, a leading science and technology company, today announced that it has opened the next round of applications for startup companies to participate in the global Merck Accelerator program. Startups can choose to participate in one of the two programs, either at the company's Innovation Center at global headquarters in Darmstadt or at its China Innovation Hub in Shanghai. (Source: eHealth News EU)
Source: eHealth News EU - June 5, 2019 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news

Could Myriad ’s New Study Results Be Game Changers For Cancer Patients?
The 2019 American Society of Clinical Oncology’s meeting might be in the books, but the impact of some of the data released at the conference are certain to have implications for cancer patients for years to come. Myriad Genetics presented data from several studies at ASCO that will no doubt have a long-lasting impact on cancer detection and treatment. The Salt Lake City, UT-based company spoke with MD+DI during ASCO about results from both colorectal cancer and breast cancer studies. Some of the most talked-about results came from the Phase III POLO Study, which looked at how well the BRACAnalysis CDx id...
Source: MDDI - June 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

FDA expands Merck antibiotic indication to pneumonia treatment
The previously FDA-approved drug, Zerbaxa, is now indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 4, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Monday, June 3, 2019 -- KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 3, 2019 Category: Drugs & Pharmacology Source Type: news

Merck wins U.S. FDA approval for expanded use of antibiotic
The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck& Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study
AstraZeneca and Merck& Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - June 2, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Merck's Keytruda sets new five-year survival standard for advanced lung cancer
Nearly a quarter of patients who received Merck& Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - June 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Immunotherapy improves five-year survival rate of people with advanced lung cancer
In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years — and 25% of patients whose tumor cells had a specific protein lived at least that long.When the study began in 2012, the average five-year survival rate was just 5.5%  for people with that type of cancer.The study, conducted by researchers at theUCLA Jonsson Comprehensive Cancer Center and more than 30 other centers, was the first to evaluate pembrolizumab as a treatment for lung cancer. The results were featured in aJune 1...
Source: UCLA Newsroom: Health Sciences - June 1, 2019 Category: Universities & Medical Training Source Type: news

AI+AR Equals Altoida ’s Alzheimer’s Detection Solution
Altoida is combining artificial intelligence, machine learning, and augmented reality to help detect Alzheimer’s disease. The Houston, TX-based company has struck a chord with venture capitalists, raising $6.3 million in a series A round. The financing was led by M Ventures, the corporate venture capital arm of the science and technology company Merck KGaA, Darmstadt, Germany, with participation from Grey Sky Venture Partners, VI Partners AG, Alpana Ventures, and FYRFLY Venture Partners. The new capital will be used to further expand Altoida's presence worldwide with an immediate focus on commercializati...
Source: MDDI - May 31, 2019 Category: Medical Devices Authors: Omar Ford Tags: Assembly and Automation Source Type: news

Merck pioneers new effort to see MS from the inside out
Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple Sclerosis International Federation (MSIF) to raise awareness of the 2.3 million people worldwide living with this challenging disease. In support of this year’s World MS Day theme, #MyInvisibleMS, Merck is making MS visible through a variety of initiatives aimed at shining a light on the hidden symptoms of MS. (Source: World Pharma News)
Source: World Pharma News - May 30, 2019 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Liberia: Don't Stigmatize Infertile Women
[New Dawn] An international organization, Merck Foundation, holds one-day health training for Liberian journalists from across the country held at a local hotel in Monrovia on Monday, May 27. The Foundation of which Liberia's First Lady Clar M. Weah is an Ambassador, trains over 100 journalists on reporting infertility. (Source: AllAfrica News: Pregnancy and Childbirth)
Source: AllAfrica News: Pregnancy and Childbirth - May 28, 2019 Category: OBGYN Source Type: news

Congo Wants More Use of Merck Vaccine Rather Than J & J Newcomer - Minister Congo Wants More Use of Merck Vaccine Rather Than J & J Newcomer - Minister
Democratic Republic of Congo called on Wednesday for Merck's experimental Ebola vaccine to be fully licensed to facilitate its use in the Ebola-hit country, while saying Johnson& Johnson's rival drug would complicate matters.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Congo wants more use of Merck vaccine rather than J & J newcomer: minister
Democratic Republic of Congo called on Wednesday for Merck's experimental Ebola vaccine to be fully licensed to facilitate its use in the Ebola-hit country, while saying Johnson& Johnson's rival drug would complicate matters. (Source: Reuters: Health)
Source: Reuters: Health - May 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug
The U.S. Supreme Court on Monday threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck& Co of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug Fosamax (alendronic acid).Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - May 22, 2019 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news

Merck acquires Peloton Therapeutics for $1 billion
The acquisition of Peloton, which was seeking to go public last week, brings its lead kidney cancer drug candidate to Merck, strengthening its renal cell carcinoma presence (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 21, 2019 Category: Pharmaceuticals Source Type: news

Merck to buy cancer drug developer in deal that could be worth more than $2B
Merck& Co. Inc., looking to strengthen its pipeline of cancer therapies, entered into a definitive agreement Tuesday to acquire Peloton Therapeutics in a deal that includes an upfront payment of $1.05 billion. Shareholders of Peloton will also be eligible to receive up to an additional $1.15 billion if regulatory and sales milestones are achieved for products the Dallas based company has in development. Peloton's lead new drug candidate is in late stage clinical testing as a potential treatment… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 21, 2019 Category: Biotechnology Authors: John George Source Type: news

Merck agrees $1bn deal to buy biopharmaceutical company Peloton
Group that is developing a renal cancer treatment had been planning a New York listing (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 21, 2019 Category: Pharmaceuticals Source Type: news

Merck's Keytruda fails as monotherapy in breast cancer study
Merck& Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer. (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Supreme Court sides with Merck in landmark decision
The U.S. Supreme Court gave Merck& Co. a major victory in a case that could be a milestone for further product liability claims. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 20, 2019 Category: Pharmaceuticals Source Type: news

Supreme Court gives Merck another shot to avoid Fosamax lawsuits
The U.S. Supreme Court on Monday gave Merck& Co a new opportunity to avoid lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax, throwing out a lower court decision that had revived the litigation. (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Supreme Court sends dispute over Fosamax back to lower court
The Supreme Court is sending a dispute between drugmaker Merck and patients who used its bone-strengthening drug Fosamax back to a lower court (Source: ABC News: Health)
Source: ABC News: Health - May 20, 2019 Category: Consumer Health News Tags: Health Source Type: news

Merck CEO, Ken Frazier's Unusual Priority -- Science
For a CEO to focus public remarks on science and scientists is rare. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 15, 2019 Category: Pharmaceuticals Authors: John LaMattina, Contributor Source Type: news

FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York, US, May 14, 2019– Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 14, 2019 Category: Drugs & Pharmacology Source Type: news

WHO adjusts strategy as Merck Ebola vaccine supply dwindles
WHO ’s Strategic Advisory Group of Experts has issued new recommendations to address vaccination challenges in the ongoing Ebola outbreak in the Democratic Republic of the Congo. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 10, 2019 Category: Pharmaceuticals Source Type: news

Global Health: A New Ebola Vaccine Strategy in Africa: Smaller Doses
As violence makes it harder to reach stricken villages in Congo, experts plan to stretch supplies and to give the vaccine to everyone, not just contacts of victims. (Source: NYT Health)
Source: NYT Health - May 8, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Ebola Virus Vaccination and Immunization Congo, Democratic Republic of (Congo-Kinshasa) Epidemics World Health Organization Johnson & Merck Company Inc Source Type: news

Merck Steps Up U.S. Measles Vaccine Production With Increased Demand Merck Steps Up U.S. Measles Vaccine Production With Increased Demand
Merck& Co said on Wednesday it has increased production of the measles vaccine to meet an uptick in demand in the United States in the midst of the country's biggest outbreak in 25 years.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 3, 2019 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

Fox News spreads more fake news measles hysteria by claiming MMR vaccines don't contain aborted human fetal tissue... but they actually do
(Natural News) Doing its part to shill ridiculous fake news on behalf of the lying vaccine industry, Fox News recently published a shameless propaganda piece about the ongoing measles “outbreak,” which falsely claims that the MMR vaccine for measles, mumps, and rubella, manufactured by Merck & Co., doesn’t contain aborted human fetal tissue – even... (Source: NaturalNews.com)
Source: NaturalNews.com - May 3, 2019 Category: Consumer Health News Source Type: news

Merck to cut jobs, close plants with $1.2B restructuring plan
Merck and Co. has created a restructuring plan it says is designed to optimize its manufacturing operations. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 2, 2019 Category: Pharmaceuticals Source Type: news